Alkermes plc
NASDAQ:ALKSBiotechnology
+$0.79 today
- Market cap
- $7.87B
- Beta
- 0.33
- P/E (TTM)
- 49.1
- EPS (TTM)
- $0.92
Volume 1.39M
Average 2.33M
ALKS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Alkermes plcNASDAQ: ALKS
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA declines year over year
Q3 FY2026 EBITDA of $69.45M fell 36.2% year over year, ahead of the -59.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 27.8% from the prior quarter. Over 3 fiscal years it compounded at +76.9% a year.
Context
- EBITDA amounted to 22.4% of revenue in FY2025, down 9.4 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 14 analysts of -$26.54M (-108.0%) for the fiscal year ending Dec 2026, a slowdown from the -33.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $69.45M+27.8% QoQ
- Last fiscal yearDec 2025
- $330.89M-33.1% YoY
- LTMSep 2026
- $178.67M-59.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -36.2% | -82.2% | -46.0 pp |
| 1 year | -33.1% | -108.0% | -74.9 pp |
| 3-year CAGR | +76.9% | +27.8% | -49.1 pp |
| 5-year CAGR | +18.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 330.89M USD
- Year-over-year change
- -33.1%
- 4-year CAGR
- +16.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 330.89M | -33.1% |
| FY2024 | 2024-12-31 | 494.86M | -4.7% |
| FY2023 | 2023-12-31 | 519.48M | +769.1% |
| FY2022 | 2022-12-31 | 59.77M | -66.3% |
| FY2021 | 2021-12-31 | 177.6M | — |
EBITDA vs competitors
How ALKS compares with its peers on the latest reported figures
- ALKS's LTM Sep 2026 EBITDA of $178.67M is the 3rd highest of the 7 companies compared; the peer median is $62.21M.
- Its year-over-year change of -59.0% is the 5th highest of 7, against a peer median of +14.0%.
- EBITDA amounts to 10.2% of revenue for ALKS, versus a peer median of 21.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $990.56M | +284.7% | -43.7% | 21.0% | |
| LTM Sep 2026 | $949.9M | +39.8% | +41.2% | 25.7% | |
| LTM Sep 2026 | $178.67M | -59.0% | +76.9% | 10.2% | |
| LTM Sep 2026 | $140.29M | +5.0% | — | 11.7% | |
| LTM Jun 2026 | -$15.87M | -109.6% | -34.8% | 1.9% | |
| LTM Mar 2026 | -$136.24M | -213.5% | — | 62.6% | |
| LTM Jun 2026 | -$176.13M | +22.9% | — | 22.7% | |
| Peer median (excluding ALKS) | $62.21M | +14.0% | -34.8% | 21.8% | |
Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.11B | 1.66B | 1.56B | 1.48B |
| Cost of Revenue | 197.32M | 218.07M | 253.04M | 245.33M | 196.46M |
| Gross Profit | 976.43M | 893.73M | 1.41B | 1.31B | 1.28B |
| Gross Margin | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% |
| Research & Development | 290.92M | 272.7M | 270.81M | 245.33M | 323.96M |
| Selling, General & Admin | 549.61M | 590.75M | 689.75M | 645.24M | 714.52M |
| Operating Expenses | 878.68M | 899.82M | 996.25M | 891.67M | 1.03B |
| Depreciation & Amortization | 78.65M | 77.86M | 74.93M | 28.53M | 27.17M |
| EBITDA | 177.6M | 59.77M | 519.48M | 494.86M | 330.89M |
| EBITDA Margin | 15.1% | 5.4% | 31.2% | 31.8% | 22.4% |
| Operating Income | 97.75M | (6.09M) | 414.12M | 420.64M | 253.96M |
| Operating Margin | 8.3% | -0.5% | 24.9% | 27.0% | 17.2% |
| Interest Income | 2.41M | 7.63M | 30.85M | 42.45M | 45.3M |
| Interest Expense | 11.22M | 13.04M | 23.03M | 22.58M | 12.28M |
| Other Income / Expenses | (10.02M) | (25.04M) | 7.4M | 23.11M | 37.49M |
| Income Before Tax | 87.73M | (31.13M) | 421.52M | 443.75M | 291.45M |
| Pre-Tax Margin | 7.5% | -2.8% | 25.3% | 28.5% | 19.7% |
| Income Tax Expense | 11.33M | 2.02M | (97.64M) | 71.61M | 49.79M |
| Net Income | (48.17M) | (158.27M) | 355.76M | 367.07M | 241.66M |
| Net Margin | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% |
| EPS (Basic) | (0.30) | (0.97) | 2.14 | 2.22 | 1.47 |
| EPS (Diluted) | (0.30) | (0.97) | 2.10 | 2.17 | 1.43 |
| Weighted Avg Shares | 160.94M | 163.74M | 166.22M | 165.39M | 164.7M |
| Weighted Avg Shares (Diluted) | 160.94M | 163.74M | 169.73M | 169.2M | 168.74M |
Alkermes plc
NASDAQ:ALKS
Intrinsic Alpha fair value
Locked
Current Price
$46.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.